Cargando…
Combating escalating harms associated with pharmaceutical opioid use in Australia: the POPPY II study protocol
INTRODUCTION: Opioid prescribing has increased 15-fold in Australia in the past two decades, alongside increases in a range of opioid-related harms such as opioid dependence and overdose. However, despite concerns about increasing opioid use, extramedical use and harms, there is a lack of population...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286479/ https://www.ncbi.nlm.nih.gov/pubmed/30518593 http://dx.doi.org/10.1136/bmjopen-2018-025840 |
_version_ | 1783379461871239168 |
---|---|
author | Gisev, Natasa Pearson, Sallie-Anne Dobbins, Timothy Currow, David C Blyth, Fiona Larney, Sarah Dunlop, Adrian Mattick, Richard P Wilson, Andrew Degenhardt, Louisa |
author_facet | Gisev, Natasa Pearson, Sallie-Anne Dobbins, Timothy Currow, David C Blyth, Fiona Larney, Sarah Dunlop, Adrian Mattick, Richard P Wilson, Andrew Degenhardt, Louisa |
author_sort | Gisev, Natasa |
collection | PubMed |
description | INTRODUCTION: Opioid prescribing has increased 15-fold in Australia in the past two decades, alongside increases in a range of opioid-related harms such as opioid dependence and overdose. However, despite concerns about increasing opioid use, extramedical use and harms, there is a lack of population-level evidence about the drivers of long-term prescribed opioid use, dependence, overdose and other harms. METHODS AND ANALYSIS: We will form a cohort of all adult residents in New South Wales (NSW), Australia, who initiated prescribed opioids from 2002 using Pharmaceutical Benefits Scheme dispensing records. This cohort will be linked to a wide range of other datasets containing information on sociodemographic and clinical characteristics, health service use and adverse outcomes (eg, opioid dependence and non-fatal and fatal overdose). Analyses will initially examine patterns and predictors of prescribed opioid use and then apply regression and survival analysis to quantify the risks and risk factors of adverse outcomes associated with prescribed opioid use. ETHICS AND DISSEMINATION: This study has received full ethical approval from the Australian Institute of Health and Welfare Ethics Committee, the NSW Population and Health Services Research Committee and the ACT Health Human Research Ethics Committee. This will be the largest postmarketing surveillance study of prescribed opioids undertaken in Australia, linking exposure and outcomes and examining risk factors for adverse outcomes of prescribed opioids. As such, this work has important translational promise, with direct relevance to regulatory authorities and agencies worldwide. Project findings will be disseminated at scientific conferences and in peer-reviewed journals. We will also conduct targeted dissemination with policy makers, professional bodies and peak bodies in the pain, medicine and addiction fields through stakeholder workshops and advisory groups. Results will be reported in accordance with the REporting of studies Conducted using Observational Routinely collected Data (RECORD) Statement. |
format | Online Article Text |
id | pubmed-6286479 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-62864792018-12-26 Combating escalating harms associated with pharmaceutical opioid use in Australia: the POPPY II study protocol Gisev, Natasa Pearson, Sallie-Anne Dobbins, Timothy Currow, David C Blyth, Fiona Larney, Sarah Dunlop, Adrian Mattick, Richard P Wilson, Andrew Degenhardt, Louisa BMJ Open Public Health INTRODUCTION: Opioid prescribing has increased 15-fold in Australia in the past two decades, alongside increases in a range of opioid-related harms such as opioid dependence and overdose. However, despite concerns about increasing opioid use, extramedical use and harms, there is a lack of population-level evidence about the drivers of long-term prescribed opioid use, dependence, overdose and other harms. METHODS AND ANALYSIS: We will form a cohort of all adult residents in New South Wales (NSW), Australia, who initiated prescribed opioids from 2002 using Pharmaceutical Benefits Scheme dispensing records. This cohort will be linked to a wide range of other datasets containing information on sociodemographic and clinical characteristics, health service use and adverse outcomes (eg, opioid dependence and non-fatal and fatal overdose). Analyses will initially examine patterns and predictors of prescribed opioid use and then apply regression and survival analysis to quantify the risks and risk factors of adverse outcomes associated with prescribed opioid use. ETHICS AND DISSEMINATION: This study has received full ethical approval from the Australian Institute of Health and Welfare Ethics Committee, the NSW Population and Health Services Research Committee and the ACT Health Human Research Ethics Committee. This will be the largest postmarketing surveillance study of prescribed opioids undertaken in Australia, linking exposure and outcomes and examining risk factors for adverse outcomes of prescribed opioids. As such, this work has important translational promise, with direct relevance to regulatory authorities and agencies worldwide. Project findings will be disseminated at scientific conferences and in peer-reviewed journals. We will also conduct targeted dissemination with policy makers, professional bodies and peak bodies in the pain, medicine and addiction fields through stakeholder workshops and advisory groups. Results will be reported in accordance with the REporting of studies Conducted using Observational Routinely collected Data (RECORD) Statement. BMJ Publishing Group 2018-12-04 /pmc/articles/PMC6286479/ /pubmed/30518593 http://dx.doi.org/10.1136/bmjopen-2018-025840 Text en © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Public Health Gisev, Natasa Pearson, Sallie-Anne Dobbins, Timothy Currow, David C Blyth, Fiona Larney, Sarah Dunlop, Adrian Mattick, Richard P Wilson, Andrew Degenhardt, Louisa Combating escalating harms associated with pharmaceutical opioid use in Australia: the POPPY II study protocol |
title | Combating escalating harms associated with pharmaceutical opioid use in Australia: the POPPY II study protocol |
title_full | Combating escalating harms associated with pharmaceutical opioid use in Australia: the POPPY II study protocol |
title_fullStr | Combating escalating harms associated with pharmaceutical opioid use in Australia: the POPPY II study protocol |
title_full_unstemmed | Combating escalating harms associated with pharmaceutical opioid use in Australia: the POPPY II study protocol |
title_short | Combating escalating harms associated with pharmaceutical opioid use in Australia: the POPPY II study protocol |
title_sort | combating escalating harms associated with pharmaceutical opioid use in australia: the poppy ii study protocol |
topic | Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286479/ https://www.ncbi.nlm.nih.gov/pubmed/30518593 http://dx.doi.org/10.1136/bmjopen-2018-025840 |
work_keys_str_mv | AT gisevnatasa combatingescalatingharmsassociatedwithpharmaceuticalopioiduseinaustraliathepoppyiistudyprotocol AT pearsonsallieanne combatingescalatingharmsassociatedwithpharmaceuticalopioiduseinaustraliathepoppyiistudyprotocol AT dobbinstimothy combatingescalatingharmsassociatedwithpharmaceuticalopioiduseinaustraliathepoppyiistudyprotocol AT currowdavidc combatingescalatingharmsassociatedwithpharmaceuticalopioiduseinaustraliathepoppyiistudyprotocol AT blythfiona combatingescalatingharmsassociatedwithpharmaceuticalopioiduseinaustraliathepoppyiistudyprotocol AT larneysarah combatingescalatingharmsassociatedwithpharmaceuticalopioiduseinaustraliathepoppyiistudyprotocol AT dunlopadrian combatingescalatingharmsassociatedwithpharmaceuticalopioiduseinaustraliathepoppyiistudyprotocol AT mattickrichardp combatingescalatingharmsassociatedwithpharmaceuticalopioiduseinaustraliathepoppyiistudyprotocol AT wilsonandrew combatingescalatingharmsassociatedwithpharmaceuticalopioiduseinaustraliathepoppyiistudyprotocol AT degenhardtlouisa combatingescalatingharmsassociatedwithpharmaceuticalopioiduseinaustraliathepoppyiistudyprotocol |